Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Computational approach based on freely accessible tools for antimicrobial drug design R2

A Chronicle Review of In-Silico Approaches for Discovering Novel Antimicrobial Agents to Combat Antimicrobial Resistance

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

AutoMolDesigner for Antibiotic Discovery: an AI-based Open-source Software for Automated Design of Small-molecule Antibiotics

In Silico Discovery of Novel Ligands for Antimicrobial Lipopeptides for Computer-Aided Drug Design

Molecular guidelines for promising antimicrobial agents

Computational Strategies in Drug Discovery: Leveraging Subtractive Genomic Analysis for Target Identification

Integrated computational approaches for advancing antimicrobial peptide development

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Computational Methods and Tools in Antimicrobial Peptide Research

The role and potential of computer-aided drug discovery strategies in the discovery of novel antimicrobials

Uncovering the secrets of resistance: An introduction to computational methods in infectious disease research

Open access in silico tools to predict the ADMET profiling of drug candidates

In Silico Prediction, Characterization, and Molecular Docking Studies on New Benzamide Derivatives

In Silico Design of Antimicrobial Oligopeptides Based on 3D-QSAR Modeling and Bioassay Evaluation

Computer-aided drug repurposing to tackle antibiotic resistance based on topological data analysis

From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP Design and Selectivity

From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP De- sign and Selectivity

In silico screening of protein-binding peptides with an application to developing peptide inhibitors against antibiotic resistance

Bioinformatics approaches for new drug discovery: a review